期刊
LEUKEMIA
卷 18, 期 3, 页码 460-465出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2403239
关键词
myelodysplastic syndromes; immune modulation; antithymocyte globulin
Immunosuppression has recently been proposed for low-risk myelodysplastic syndromes (MDS) to reverse bone marrow failure by inhibiting intramedullary secretion of proapoptotic cytokines. We treated 35 MDS patients ( 24 refractory anaemia ( RA), 10 RA with excess blasts and one chronic myelomonocytic leukaemia) with either horse antithymocyte globulin 15 mg/kg/day or rabbit antithymocyte globulin 3.75 mg/kg/day, each for 5 days. Median age was 63 years ( range: 41 - 75). After 1 to 34+ months of follow-up ( mean: 15+), four patients experienced complete haematological responses (CR), six good responses (GR) and two minor responses. All CRs and GRs occurred in patients with RA, in whom both horse and rabbit ATG yielded five responses out of 12 (42%). Time to response varied between 1 and 10 ( mean: 3) months. The median duration of response was 9+ ( 1 -17+) months; five patients are in continuing response. In all, 23 patients suffered side effects >degreesII WHO ( the degree of toxicity encountered according to the internationally accepted WHO toxicity grading); one patient died 2 weeks after rabbit ATG from rhinocerebral mucormycosis. Parameters that correlated with response were duration of disease and RA subgroup. In our experience, immune-modulating therapy with either horse or rabbit ATG is feasible in patients with RA and short duration of disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据